{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:27:06Z","timestamp":1794673626275,"version":"4.9.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.2515\/therapie:2007025","type":"journal-article","created":{"date-parts":[[2007,6,20]],"date-time":"2007-06-20T14:48:32Z","timestamp":1182350912000},"page":"105-109","source":"Crossref","is-referenced-by-count":2,"title":["Pour ou contre le ph\u00e9notypage\/g\u00e9notypage des patients trait\u00e9s par le 5-fluorouracile pour pr\u00e9venir les effets ind\u00e9sirables ?"],"prefix":"10.1016","volume":"62","author":[{"given":"Romain","family":"Coriat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Chaussade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2007025_bb0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N","article-title":"Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU","volume":"77","author":"Gamelin","year":"1996","journal-title":"Cancer"},{"key":"10.2515\/therapie:2007025_bb0010","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1994.12.6.1291","article-title":"Relationship between fluorouracil systemic exposure and tumor response and patient survival","volume":"12","author":"Milano","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.2515\/therapie:2007025_bb0015","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study","volume":"15","author":"de Gramont","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.2515\/therapie:2007025_bb0020","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.2515\/therapie:2007025_bb0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1432-1033.1989.tb15105.x","article-title":"Purification and characterization of dihydropyrimidine dehydrogenase from pig liver","volume":"185","author":"Podschun","year":"1989","journal-title":"Eur J Biochem"},{"key":"10.2515\/therapie:2007025_bb0030","doi-asserted-by":"crossref","first-page":"17102","DOI":"10.1016\/S0021-9258(18)41899-6","article-title":"Purification and characterization of dihydropyrimidine dehydrogenase from human liver","volume":"267","author":"Lu","year":"1992","journal-title":"J Biol Chem"},{"key":"10.2515\/therapie:2007025_bb0035","first-page":"231","article-title":"Oral 5-FU and digestive cancers","volume":"28","author":"Taieb","year":"2004","journal-title":"Gastroenterol Clin Biol"},{"key":"10.2515\/therapie:2007025_bb0040","first-page":"38","article-title":"5-fluorouracil: metabolism and current indications in digestive cancer treatment","volume":"26","author":"Aparicio","year":"2002","journal-title":"Gastroenterol Clin Biol"},{"key":"10.2515\/therapie:2007025_bb0045","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1124\/dmd.30.11.1221","article-title":"Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine","volume":"30","author":"Desmoulin","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.2515\/therapie:2007025_bb0050","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/030089169608200507","article-title":"A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease","volume":"82","author":"Bajetta","year":"1996","journal-title":"Tumori"},{"key":"10.2515\/therapie:2007025_bb0055","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/368198a0","article-title":"Angiogenic activity of enzymes","volume":"368","author":"Haraguchi","year":"1994","journal-title":"Nature"},{"key":"10.2515\/therapie:2007025_bb0060","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res"},{"key":"10.2515\/therapie:2007025_bb0065","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene","volume":"6","author":"van Kuilenburg","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.2515\/therapie:2007025_bb0070","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.2515\/therapie:2007025_bb0075","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bjc.6690098","article-title":"Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity","volume":"79","author":"Milano","year":"1999","journal-title":"Br J Cancer"},{"key":"10.2515\/therapie:2007025_bb0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","article-title":"Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil","volume":"41","author":"Johnson","year":"2001","journal-title":"Adv Enzyme Regul"},{"key":"10.2515\/therapie:2007025_bb0085","first-page":"2832","article-title":"Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2019-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls","volume":"7","author":"Raida","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.2515\/therapie:2007025_bb0090","first-page":"5405","article-title":"Enzymes of uracil catabolism in normal and neoplastic human tissues","volume":"45","author":"Naguib","year":"1985","journal-title":"Cancer Res"},{"key":"10.2515\/therapie:2007025_bb0095","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1016\/0006-2952(88)90349-8","article-title":"Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy","volume":"37","author":"Harris","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"10.2515\/therapie:2007025_bb0100","first-page":"2899","article-title":"Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients","volume":"52","author":"Fleming","year":"1992","journal-title":"Cancer Res"},{"key":"10.2515\/therapie:2007025_bb0105","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"EtienneMC","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.2515\/therapie:2007025_bb0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.patbio.2004.12.031","article-title":"Dihydropyrimidine deshydrogenase (DPD): rhythm and consequences","volume":"53","author":"Barrat-Petit","year":"2005","journal-title":"Pathol Biol (Paris)"},{"key":"10.2515\/therapie:2007025_bb0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","article-title":"Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity","volume":"81","author":"Diasio","year":"1988","journal-title":"J Clin Invest"},{"key":"10.2515\/therapie:2007025_bb0120","first-page":"1149","article-title":"Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency afteradministration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency","volume":"7","author":"van Kuilenburg","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.2515\/therapie:2007025_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00008711","article-title":"Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency","volume":"104","author":"Van Kuilenburg","year":"1999","journal-title":"Hum Genet"},{"key":"10.2515\/therapie:2007025_bb0130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10269-005-0149-5","article-title":"Pharmacog\u00e9n\u00e9tique du m\u00e9tabolisme des pyrimidines. La dyhydropyrimidine d\u00e9shydrog\u00e9nase","volume":"7","author":"Gamelin","year":"2005","journal-title":"Oncologie"},{"key":"10.2515\/therapie:2007025_bb0135","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/jnci\/85.19.1602","article-title":"Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency","volume":"85","author":"Houyau","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.2515\/therapie:2007025_bb0140","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198507253130407","article-title":"Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity","volume":"313","author":"Tuchman","year":"1985","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie:2007025_bb0145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F","article-title":"Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome","volume":"68","author":"Harris","year":"1991","journal-title":"Cancer"},{"key":"10.2515\/therapie:2007025_bb0150","first-page":"477","article-title":"Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency","volume":"2","author":"Takimoto","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.2515\/therapie:2007025_bb0155","first-page":"1593","article-title":"Fluoropyrimidines-related severe toxicity. Comparison of different methods for detecting dihydropyrimidine dehydrogenase (DPD) deficiency and predicting 5-FU metabolism","volume":"43","author":"Boisdron-Celle","year":"2002","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.2515\/therapie:2007025_bb0160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200004000-00002","article-title":"Known variant DPYD alleles do not explain DPD deficiency in cancer patients","volume":"10","author":"Collie-Duguid","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.2515\/therapie:2007025_bb0165","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage","volume":"17","author":"van Kuilenburg","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.2515\/therapie:2007025_bb0170","first-page":"507","article-title":"Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver","volume":"2","author":"Chazal","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.2515\/therapie:2007025_bb0175","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0378-4347(01)00359-0","article-title":"High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity","volume":"762","author":"Deporte-Fety","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.2515\/therapie:2007025_bb0180","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","article-title":"Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity","volume":"696","author":"Johnson","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716304644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716304644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,15]],"date-time":"2021-08-15T05:27:59Z","timestamp":1629005279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716304644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0040595716304644"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2007025","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}